Your browser doesn't support javascript.
loading
Effects of pitavastatin on lipid profiles and high-sensitivity CRP in Japanese subjects with hypercholesterolemia: Kansai Investigation of Statin for Hyperlipidemic Intervention in Metabolism and Endocrinology (KISHIMEN) investigatars.
Koshiyama, Hiroyuki; Taniguchi, Ataru; Tanaka, Kiyoshi; Kagimoto, Shinji; Fujioka, Yoshio; Hirata, Kenichi; Nakamura, Yoshio; Iwakura, Akane; Hara, Kyoko; Yamamoto, Taizo; Kuroe, Akira; Ohya, Michihiro; Fujimoto, Shimpei; Hamamoto, Yoshiyuki; Honjo, Sachiko; Ikeda, Hiroki; Nabe, Koichiro; Tsuda, Kinsuke; Inagaki, Nobuya; Seino, Yutaka; Kume, Noriaki.
Afiliación
  • Koshiyama H; Center for Diabetes & Endocrinology, The Tazuke Kofukai Foundation Medical Research Institute Kitano Hospital, Osaka, Japan. h-koshiyama@kitano-hp.or.jp
J Atheroscler Thromb ; 15(6): 345-50, 2008 Dec.
Article en En | MEDLINE | ID: mdl-19075492
AIM: The effect of pitavastatin on high-sensitivity C-reactive protein (hs-CRP) has not been reported, yet, in humans. We, therefore, investigated the effects of pitavastatin on lipid profiles and hs-CRP in Japanese subjects with hypercholesterolemia. METHODS: The subjects were 178 Japanese with hypercholesterolemia, including 103 (58%) with type 2 diabetes. Pitavastatin (12 mg/day) was administered for 12 months. Serum low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), remnant-like particle cholesterol (RLP-C), triglycerides (TG) and hs-CRP levels were measured for 12 months. RESULTS: Serum LDL-C and RLP-C levels were significantly decreased by 30.3% and 22.8%, respectively. Serum TG levels were decreased by 15.9% in subjects with basal TG levels above 150 mg/dl. Serum HDL-C levels were significantly increased. The administration of pitavastatin reduced serum hs-CRP levels by 34.8%. No serious adverse events were observed, including changes in glycosylated hemoglobin levels of diabetic patients. CONCLUSION: These results suggest that pitavastatin significantly improves lipid profiles and reduces proinflammatory responses, without adverse effects, in Japanese subjects with hypercholesterolemia, including those with diabetes mellitus.
Asunto(s)
Buscar en Google
Añadir a Mi BVS
Imprimir
XML
PubMed Links

Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Quinolinas / Proteína C-Reactiva / Inhibidores de Hidroximetilglutaril-CoA Reductasas / Hipercolesterolemia / Lípidos Tipo de estudio: Clinical_trials / Diagnostic_studies / Observational_studies Límite: Aged / Female / Humans / Male / Middle aged País/Región como asunto: Asia Idioma: En Revista: J Atheroscler Thromb Asunto de la revista: ANGIOLOGIA Año: 2008 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Japón
Buscar en Google
Añadir a Mi BVS
Imprimir
XML
PubMed Links

Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Quinolinas / Proteína C-Reactiva / Inhibidores de Hidroximetilglutaril-CoA Reductasas / Hipercolesterolemia / Lípidos Tipo de estudio: Clinical_trials / Diagnostic_studies / Observational_studies Límite: Aged / Female / Humans / Male / Middle aged País/Región como asunto: Asia Idioma: En Revista: J Atheroscler Thromb Asunto de la revista: ANGIOLOGIA Año: 2008 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Japón